[No standalone website (unbranded, no questionnaire)] A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site

Study’s contact

Call center

800-633-1610

Email address

Contact-US@sanofi.com

Condition

Type 2 Diabetes Mellitus

Treatment type

Interventional

Investigational product

INSULIN GLARGINE/LIXISENATIDE HOE901/AVE0010

Phase

Phase 3

Sponsor

Sanofi

ClinicalTrials.gov identifier

NCT03767543

Study number

LPS15544

Understanding clinical trials

Get answers to your questions about clinical trials.

About the study

Primary Objective: To demonstrate that the simple daily titration algorithm is non-inferior to the weekly titration algorithm according to Canadian labeling. Secondary Objective: To gain additional information on the efficacy and safety of using a simple patient-titration protocol for administration of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi).

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria
  1. Adult subject ≥ 18 years
  2. Patients with type 2 diabetes mellitus (T2DM) based on Diabetes Canada 2018 Clinical Practice Guidelines criteria and diagnosed at least 6 months prior to the screening visit
  3. Uncontrolled glycemia with an A1c ≥7.5% and ≤10.5%
  4. Patients treated for at least 6 months on any basal insulin (including but not limited to insulin glargine, Toujeo®, Degludec®, etc.) ± oral anti-diabetic drug (OADs)
  5. The total basal insulin dose must be ≤ 40 units/day
  6. The OADs allowed at inclusion are metformin, insulin secretagogues, dipeptidyl-peptidase-4 inhibitors (DPP4) inhibitors and SGLT2 inhibitors; with no change in OAD dose for at least 2 months prior to randomization
  7. Body mass index (BMI) between 20 kg/m2 and 40 kg/m2 inclusively
Exclusion criteria
  1. History of severe hypoglycemia or hypoglycemia unawareness
  2. History of metabolic acidosis, including diabetic ketoacidosis within 1 year prior to screening visit
  3. Current or previous (known intolerance to GLP-1s) treatment with glucagon like peptide-1 (GLP-1) receptor agonist
  4. Current use of rapid-acting insulin or premix insulins or use of these insulins within 3 months prior to the screening visit
  5. Use of systemic glucocorticoids (excluding topical and inhaled forms) for a total duration of 1 week or more within 3 months prior to the screening visit
  6. Use of weight loss drugs within 3 months prior to the screening visit
  7. Patients with conditions/concomitant diseases that will affect safe participation in this study (e.g. active malignant tumor, major systemic diseases, presence of clinically significant diabetic retinopathy or presence of macular edema likely to require treatment within the study period, etc.)
  8. Women of childbearing potential (WOCBP) not protected by an effective contraceptive method of birth control and/or who are unwilling or unable to be tested for pregnancy
  9. Positive serum pregnancy test in WOCBP, pregnancy or lactation
  10. Clinically relevant history of gastrointestinal disease associated with prolonged nausea and vomiting, including (but not limited to): gastroparesis, unstable (i.e. worsening) or uncontrolled (i.e. prolonged nausea and vomiting) gastroesophageal reflux disease requiring medical treatment within 6 months prior to the time of screening visit
  11. History of pancreatitis (unless pancreatitis was related to gallstones and treated with cholecystectomy), pancreatitis during previous treatment with incretin therapies, chronic pancreatitis, pancreatectomy, or stomach/gastric surgery
  12. Personal or immediate family history of medullary thyroid cancer or genetic conditions that predispose the patient to medullary thyroid cancer (e.g. multiple endocrine neoplasia syndromes) The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site